Experts describe how the tumor microenvironment modulates clinical responses and how patient-derived ex vivo and engineered in vitro models can be used for pre-clinical immuno-oncology testing.
Dr. Nataliia Beztsinna and Dr. Marten Hornsveld describe the role of tumor microenvironment (TME) compartments in clinical responses, as well as ex vivo patient-derived tissue technologies capable of maintaining the native TME for pre-clinical testing. Complex in vitro models with the use of human stromal and immune co-cultures are discussed, together with the advantages of HCI to quantify intact tumor biology.
Key Topics Include:
- Examine the key components of the TME that affect immunotherapy responses. Discuss the main approaches to analyse the TME composition and the differences between ‘hot’ and ‘cold’ solid tumors
- Identify ex vivo assays capable of maintaining native human TME. Discuss the advantages of high content imaging assay on fresh patient tissue in 3D for deciphering complex immuno-oncology drug responses
- Comparison between in vitro based assays containing native TME or reconstituted TME
- How myeloid cells in the TME affect tumors and methods to study and target this compartment
- Advances in modelling the mesenchymal TME compartment in vitro and constructing pre-clinical mini-tumor platforms
Resources
Presenters
Associate Director / Head of 3D Ex vivo Patient Tissue Platform
Crown Bioscience
Dr. Nataliia Beztsinna has a MS degree in Biochemistry and PhD in Biology-Chemistry interface. She is experienced in confocal microscopy, high content imaging, 3D cell culture, organoids, molecular imaging, primary patient tissue cultures, in vitro and in vivo cancer models and tumor- targeted drug delivery nanosystems. Currently Nataliia is working as a Head of 3D Ex Vivo Patient Tissue (EVPT) Platform. Her responsibilties include managing a small team of highly-skilled scientists, ensuring high quality execution of customer projects, interactions, technical advising and quote design for potential customers as well as research and development activities dedicated to the growth of the EVPT Platform.
Senior Scientist, Oncology
Crown Bioscience
Dr. Marten Hornsveld is a molecular biologist that focuses on understanding and targeting molecular signal transduction in cancer. During his PhD program, he studied the role of PI3K-AKT signaling in breast cancer using a variety of mouse and cell based models. In his postdoctoral research he moved into the organoid technology field and worked on building representative organoid models for pancreatic cancer. This resulted in the establishment of a novel close-to-patient mini-tumor model that can be employed for both basic research and pre-clinical studies. A year ago, he switched gears and started as a senior scientist at Crown Bioscience. Here, he continues to work on building pre-clinical tumor models to facilitate rapid discovery of promising lead compounds in the oncology field.
Production Partner
Crown Bioscience
Crown Bioscience brings clarity to drug discovery around the world by helping biopharmaceutical companies solve some of today's most pressing challenges in oncology, inflammation, cardiovascular, and metabolic disease. Our premier Translational Platforms help our clients accelerate their new drug development programs.
Additional Content From Crown Bioscience
What’s Next in Preclinical Cancer Immunotherapy Research?
This webinar will include a panel discussion of key topics in the field of cancer immunotherapy, including new and emerging methods, recent publications, and future directions.
Targeting T Cells Within the Cancer Immunity Cycle
In this webinar, speakers will discuss the role of T cell biology in cancer immunotherapy.
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
Experts provide an overview of ex vivo and in vitro methods, techniques, and model systems for research within the cancer-immunity cycle framework.
Additional Content From Scientist.com
Synthetic Peptide Growth Factors: Forging the Path Forward for Regenerative Medicine, Cell Therapy, and Cellular Agriculture
Experts discuss how synthetic growth factors work and share application examples and data using these synthetic peptides for cell therapy and regenerative medicine.
The 3D DILI Model of Success – from Biological Relevance to Industry Application
Dr. Anna Borgström and Dr. Frauke Greve present the latest advancements in hepatic safety assessment using 3D liver spheroids.
It’s Life, but Not As We Know It: How Predictive Human Organ Models Are Transforming and Reshaping the Efficiency of Drug Discovery
Dr. Audrey Dubourg and Dr. Gareth Guenigault explore the value that an organ-on-a-chip approach can bring to drug discovery and development workflows, and how the regulatory landscape is shifting to encourage their widespread adoption.
Related Content
Colorectal Tumor Imaging
Join Jessica Freeling as she discusses several models of colorectal cancer in mice and their imaging methods.
Contrast-Enhanced Bladder Tumor Imaging
Join Massimo Alfano, PhD, as he discusses a novel platform for bladder tumor imaging.
Pancreatic Tumor and Therapy Monitoring
Join Dr. Srivalleesha Mallidi as she discusses advances in pancreatic cancer therapies using ultrasound-guided photoacoustic imaging.